{"page_content": "Zealand Pharma\u2019s \nR&D platform and pipeline\nPeptide platform  15\nZea\nland Pharma pipeline\n 19\nSev\nere Hypoglycemia in diabetes/Zegalouge\n 20\nCo\nngenital Hyperinsulinism (CHI)\n 21\nType 1 diabetes\n 22\nObesi\nty / Type 2 diabetes\n 23\nSho\nrt Bowel Syndrome (SBS)\n 2414\nZealand Pharma  \u221e  Annual Report 2021Zealand Pharma\u2019s R&D platform and pipeline", "metadata": {"source": "NASDAQ_ZEAL_2021.pdf", "page": 13, "parser": "pypdf", "split_method": "page", "run_time": "2024-05-29 08:35:04"}, "type": "Document"}